{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:21:58Z","timestamp":1794828118898,"version":"4.9.1"},"reference-count":81,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma, often characterized by a pattern of continued relapse after front-line chemoimmunotherapy. Although patients are usually able to regain durable disease control with covalent Bruton\u2019s tyrosine kinase inhibitors (cBTKi) at first relapse, it is now appreciated that such responses are often not sustained and the management of such patients represents a significant area of unmet need. There is an imperative to better understand resistance mechanisms and identify high-risk subsets of patients for whom cBTKi responses may be particularly short. Allogeneic stem cell transplant has an established role in appropriate candidates; however, contemporary consensus is to preferentially offer chimeric antigen receptor (CAR) T-cell therapy. In this Review, we consider the available data on both existing and emerging treatment options, including non-covalent BTK inhibitors, bispecific antibodies, antibody-drug conjugates and Bcl-2 inhibitors, and propose a treatment strategy, prioritizing clinical trials where available.<\/jats:p>","DOI":"10.3324\/haematol.2024.286205","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:40:51Z","timestamp":1731555651000},"page":"576-587","source":"Crossref","is-referenced-by-count":4,"title":["\u201cThe End of the Golden Weather\u201d: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors"],"prefix":"10.3324","volume":"110","author":[{"given":"Brian T.","family":"Grainger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"72828","doi-asserted-by":"crossref","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016; 34(11):1256-1269.","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"72829","doi-asserted-by":"crossref","unstructured":"Eyre TA, Bishton MJ, McCulloch R. Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline. Br J Haematol. 2024; 204(1):108-126.","DOI":"10.1111\/bjh.19131"},{"key":"72830","doi-asserted-by":"crossref","unstructured":"Baggio D, Wellard C, Chung E. Australian experience with ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leuk Lymphoma. 2023; 64(3):621-627.","DOI":"10.1080\/10428194.2022.2157676"},{"key":"72831","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"72832","doi-asserted-by":"crossref","unstructured":"Wang M, Rule S, Zinzani PL. Durable response with singleagent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019; 33(11):2762-2766.","DOI":"10.1038\/s41375-019-0575-9"},{"key":"72833","doi-asserted-by":"crossref","unstructured":"Song Y, Zhou K, Zou D. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139(21):3148-3158.","DOI":"10.1182\/blood.2021014162"},{"key":"72834","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling MH, Goy A. Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. Blood. 2019; 134(Suppl 1):1538.","DOI":"10.1182\/blood-2019-124691"},{"key":"72835","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling M, Goy A. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017; 179(3):430-438.","DOI":"10.1111\/bjh.14870"},{"key":"72836","doi-asserted-by":"crossref","unstructured":"Wang ML, Blum KA, Martin P. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6):739-745.","DOI":"10.1182\/blood-2015-03-635326"},{"key":"72837","doi-asserted-by":"crossref","unstructured":"McCulloch R, Eyre TA, Rule S. What causes Bruton tyrosine kinase inhibitor resistance in mantle cell lymphoma and how should we treat such patients?. Hematol Oncol Clin North Am. 2020; 34(5):923-939.","DOI":"10.1016\/j.hoc.2020.06.008"},{"key":"72838","doi-asserted-by":"crossref","unstructured":"Martin P, Maddocks K, Leonard JP. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016; 127(12):1559-1563.","DOI":"10.1182\/blood-2015-10-673145"},{"key":"72839","doi-asserted-by":"crossref","unstructured":"Cheah CY, Chihara D, Romaguera JE. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015; 26(6):1175-1179.","DOI":"10.1093\/annonc\/mdv111"},{"key":"72840","doi-asserted-by":"crossref","unstructured":"Wang M, Rule S, Zinzani PL. Durable response with singleagent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019; 33(11):2762-2766.","DOI":"10.1038\/s41375-019-0575-9"},{"key":"72841","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling M, Goy A. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019; 104(5):e211-e214.","DOI":"10.3324\/haematol.2018.205229"},{"key":"72842","doi-asserted-by":"crossref","unstructured":"Agarwal R, Dawson MA, Dreyling M, Tam CS. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leuk Lymphoma. 2018; 59(12):2769-2781.","DOI":"10.1080\/10428194.2018.1457148"},{"key":"72843","doi-asserted-by":"crossref","unstructured":"Thompson ER, Nguyen T, Kankanige Y. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. Blood Adv. 2022; 6(2):503-508.","DOI":"10.1182\/bloodadvances.2021006211"},{"key":"72844","doi-asserted-by":"crossref","unstructured":"Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023; 200(2):137-149.","DOI":"10.1111\/bjh.18418"},{"key":"72845","doi-asserted-by":"crossref","unstructured":"Zhao X, Lwin T, Silva A. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017; 8:14920.","DOI":"10.1038\/ncomms14920"},{"key":"72846","doi-asserted-by":"crossref","unstructured":"Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015; 170(4):445-456.","DOI":"10.1111\/bjh.13427"},{"key":"72847","doi-asserted-by":"crossref","unstructured":"Rahal R, Frick M, Romero R. Pharmacological and genomic profiling identifies NF-kB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014; 20(1):87-92.","DOI":"10.1038\/nm.3435"},{"key":"72848","doi-asserted-by":"crossref","unstructured":"Agarwal R, Chan YC, Tam CS. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25(1):119-129.","DOI":"10.1038\/s41591-018-0243-z"},{"key":"72849","doi-asserted-by":"crossref","unstructured":"Mohanty A, Sandoval N, Das M. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016; 7(45):73558-73572.","DOI":"10.18632\/oncotarget.12434"},{"key":"72850","doi-asserted-by":"crossref","unstructured":"Mouhssine S, Maher N, Matti BF, Alwan AF, Gaidano G. Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms. Int J Mol Sci. 2024; 25(6):3234.","DOI":"10.3390\/ijms25063234"},{"key":"72851","doi-asserted-by":"crossref","unstructured":"Jain P, Nomie K, Kotlov N. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023; 13(1):156.","DOI":"10.1038\/s41408-023-00927-2"},{"key":"72852","doi-asserted-by":"crossref","unstructured":"Bond DA, Martin P, Maddocks KJ. Relapsed mantle cell lymphoma: current management, recent progress, and future directions. J Clin Med. 2021; 10(6):1207.","DOI":"10.3390\/jcm10061207"},{"key":"72853","doi-asserted-by":"crossref","unstructured":"Dreyling M, Jurczak W, Jerkeman M. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016; 387(10020):770-778.","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"72854","doi-asserted-by":"crossref","unstructured":"Hoster E, Dreyling M, Klapper W. German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(2):558-565.","DOI":"10.1182\/blood-2007-06-095331"},{"key":"72855","doi-asserted-by":"crossref","unstructured":"Villa D, Jiang A, Visco C. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/ refractory mantle cell lymphoma. Blood. 2023; 7(16):4576-4585.","DOI":"10.1182\/bloodadvances.2023009804"},{"key":"72856","doi-asserted-by":"crossref","unstructured":"Hess LM, Chen Y, Abada PB, Konig H, Walgren RA. Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study. Adv Hematol. 2022;8262787.","DOI":"10.1155\/2022\/8262787"},{"key":"72857","doi-asserted-by":"crossref","unstructured":"McCulloch R, Visco C, Eyre TA. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020; 189(4):684-688.","DOI":"10.1111\/bjh.16416"},{"key":"72858","doi-asserted-by":"crossref","unstructured":"Tam CS, Bassett R, Ledesma C. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113(18):4144-4152.","DOI":"10.1182\/blood-2008-10-184200"},{"key":"72859","doi-asserted-by":"crossref","unstructured":"Maddukuri A, Inoue Y, Rakazawski K. Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy. J Clin Oncol. 2024; 42(Suppl 16):e19012.","DOI":"10.1200\/JCO.2024.42.16_suppl.e19012"},{"key":"72860","doi-asserted-by":"crossref","unstructured":"Lew TE, Cliff ERS, Dickinson M. T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplant. 2021; 56(11):2857-2859.","DOI":"10.1038\/s41409-021-01418-3"},{"key":"72861","doi-asserted-by":"crossref","unstructured":"Hamadani M, Saber W, Ahn KW. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013; 19(4):625-631.","DOI":"10.1016\/j.bbmt.2013.01.009"},{"key":"72862","doi-asserted-by":"crossref","unstructured":"Dreger P, Michallet M, Bosman P. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant. 2019; 54(1):44-52.","DOI":"10.1038\/s41409-018-0207-4"},{"key":"72863","doi-asserted-by":"crossref","unstructured":"Cohen JB, Shah NN, Jurczak W. Pirtobrutinib in relapsed\/ refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1\/2 BRUIN study. Blood. 2023; 142(Suppl 1):981.","DOI":"10.1182\/blood-2023-181627"},{"key":"72864","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14):1331-1342.","DOI":"10.1056\/NEJMoa1914347"},{"key":"72865","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023; 41(3):555-567.","DOI":"10.1200\/JCO.21.02370"},{"key":"72866","doi-asserted-by":"crossref","unstructured":"Long M, Beckwith K, Do P. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017; 127(8):3052-3064.","DOI":"10.1172\/JCI89756"},{"key":"72867","doi-asserted-by":"crossref","unstructured":"Ruella M, Kenderian SS, Shestova O. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016; 22(11):2684-2696.","DOI":"10.1158\/1078-0432.CCR-15-1527"},{"key":"72868","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41(14):2594-2606.","DOI":"10.1200\/JCO.22.01797"},{"key":"72869","doi-asserted-by":"crossref","unstructured":"Wang M, Siddiqi T, Gordon LI. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024; 42(10):1146-1157.","DOI":"10.1200\/JCO.23.02214"},{"key":"72870","doi-asserted-by":"crossref","unstructured":"Palomba ML, Siddiqi T, Gordon LI. Lisocabtagene maraleucel (liso-cel) in patients (pt) with R\/R mantle cell lymphoma (MCL): subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). J Clin Oncol. 2024; 42(Suppl 16):7016.","DOI":"10.1200\/JCO.2024.42.16_suppl.7016"},{"key":"72871","doi-asserted-by":"crossref","unstructured":"Hayden PJ, Roddie C, Bader P. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3):259-275.","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"72872","doi-asserted-by":"crossref","unstructured":"Lonez C, Breman E. Allogeneic CAR-T therapy technologies: has the promise been met?. Cells. 2024; 13(2):146.","DOI":"10.3390\/cells13020146"},{"key":"72873","doi-asserted-by":"crossref","unstructured":"Hu Y, Zu C, Zhang M. Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma: a first-in-human phase I study. EClinicalMedicine. 2023; 60:102010.","DOI":"10.1016\/j.eclinm.2023.102010"},{"key":"72874","doi-asserted-by":"crossref","unstructured":"Gomez EB, Ebata K, Randeria HS. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023; 142(1):62-72.","DOI":"10.1182\/blood.2022018674"},{"key":"72875","doi-asserted-by":"crossref","unstructured":"Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 2023; 141(26):3137-3142.","DOI":"10.1182\/blood.2023020240"},{"key":"72876","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Zinzani PL. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023; 41(24):3988-3997.","DOI":"10.1200\/JCO.23.00562"},{"key":"72877","doi-asserted-by":"crossref","unstructured":"Mato AR, Woyach JA, Brown JR. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Eng J Med. 2023; 389(1):33-44.","DOI":"10.1056\/NEJMoa2300696"},{"key":"72878","doi-asserted-by":"crossref","unstructured":"Roeker LE, Coombs CC, Shah NN. Safety of extended pirtobrutinib exposure in relapsed and\/or refractory B-cell malignancies. Acta Haematol. 2024; 5:1-17.","DOI":"10.1159\/000539587"},{"key":"72879","doi-asserted-by":"crossref","unstructured":"Lejeune M, K\u00f6se MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol. 2020; 11:762.","DOI":"10.3389\/fimmu.2020.00762"},{"key":"72880","doi-asserted-by":"crossref","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study. J Clin Oncol. 2025; 43(3):318-328.","DOI":"10.1200\/JCO.23.02470"},{"key":"72881","doi-asserted-by":"crossref","unstructured":"Phillips TJ, Matasar M, Eyre TA. GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma. Blood. 2023; 142(Suppl 1):3052.","DOI":"10.1182\/blood-2023-173946"},{"key":"72882","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"72883","doi-asserted-by":"crossref","unstructured":"Wang ML, Assouline S, Kamdar M. Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study. Blood. 2023; 142(Suppl 1):734.","DOI":"10.1182\/blood-2023-174956"},{"key":"72884","doi-asserted-by":"crossref","unstructured":"Hutchings M, Mous R, Clausen MR. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021; 398(10306):1157-1169.","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"72885","doi-asserted-by":"crossref","unstructured":"Ayyappan S, Kim WS, Kim TM. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/ refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2023; 142(Suppl 1):436.","DOI":"10.1182\/blood-2023-179818"},{"key":"72886","doi-asserted-by":"crossref","unstructured":"Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. J Pers Med. 2021; 11(8):764.","DOI":"10.3390\/jpm11080764"},{"key":"72887","doi-asserted-by":"crossref","unstructured":"Woyach JA, Stephens DM, Flinn IW. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Cancer Discov. 2024; 14(1):66-75.","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"72888","doi-asserted-by":"crossref","unstructured":"Danilov A, Tees MT, Patel K. A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies. Blood. 2023; 142(Suppl 1):4463.","DOI":"10.1182\/blood-2023-179872"},{"key":"72889","unstructured":"Profitos-Peleja N, Parra J, Riberio M. The multikinase CDK4\/6 inhibitor narazaciclib overcomes BTK-i resistance in mantle cell lymphoma by targeting USP24-P53 signalling axis. Hemasphere. 2024; 8(S1):P1272."},{"key":"72890","doi-asserted-by":"crossref","unstructured":"Seymour JF, Cheah CY, Parrondo R. First results from a phase 1, first-in-human study of the Bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101). Blood. 2023; 142(Suppl 1):4401.","DOI":"10.1182\/blood-2023-180109"},{"key":"72891","doi-asserted-by":"crossref","unstructured":"Karvonen H, Niininen W, Murum\u00e4gi A, Ungureanu D. Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochem Soc Trans. 2017; 45(2):457-464.","DOI":"10.1042\/BST20160272"},{"key":"72892","doi-asserted-by":"crossref","unstructured":"Spurgeon S, Mei M, Barr PM. P1200: zilovertamab vedotin (mk-2140) in relapsed or refractory (r\/r) non-hodgkin lymphoma (nhl): updated results from the phase 1 waveline-001 study. Hemasphere. 2023; 7(S3):e54506b2.","DOI":"10.1097\/01.HS9.0000971696.54506.b2"},{"key":"72893","doi-asserted-by":"crossref","unstructured":"Townsend W, Leong S, Shah M. Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Blood. 2023; 142(Suppl 1):329.","DOI":"10.1182\/blood-2023-188607"},{"key":"72894","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Seymour JF. Phase I first-inhuman study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017; 35(8):826-833.","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"72895","doi-asserted-by":"crossref","unstructured":"Eyre TA, Walter HS, Iyengar S. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019; 104(2):e68-e71.","DOI":"10.3324\/haematol.2018.198812"},{"key":"72896","doi-asserted-by":"crossref","unstructured":"Cheah CY, Tam CS, Lasica M. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with CLL\/SLL: preliminary data. Blood. 2022; 140(Suppl 1):2321-2323.","DOI":"10.1182\/blood-2022-169662"},{"key":"72897","doi-asserted-by":"crossref","unstructured":"Soumerai JD, Lasica M, Opat S. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with non-Hodgkin lymphoma (NHL) or Waldenstr\u00f6m macroglobulinemia (WM): preliminary data. Blood. 2022; 140(Suppl 1):9325-9327.","DOI":"10.1182\/blood-2022-169664"},{"key":"72898","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Chen Z, Huang B. Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial. Clin Cancer Res. 2023; 29(13):2385-2393.","DOI":"10.1158\/1078-0432.CCR-22-3321"},{"key":"72899","doi-asserted-by":"crossref","unstructured":"Handunnetti SM, Anderson MA, Burbury K. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024; 144(8):867-872.","DOI":"10.1182\/blood.2023023388"},{"key":"72900","doi-asserted-by":"crossref","unstructured":"Gauthier J, Hirayama AV, Purushe J. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020; 135(19):1650-1660.","DOI":"10.1182\/blood.2019002936"},{"key":"72901","doi-asserted-by":"crossref","unstructured":"Minson A, Hamad N, Cheah CY. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024; 143(8):673-684.","DOI":"10.1182\/blood.2023021306"},{"key":"72902","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly MA, Wilson W, Burns D. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. Hemasphere. 2024; 8(6):e87.","DOI":"10.1002\/hem3.87"},{"key":"72903","doi-asserted-by":"crossref","unstructured":"McCulloch R. Post-BTK inhibitor mantle cell lymphoma: when is CAR-T not the answer?. Br J Haematol. 2023; 202(4):718-719.","DOI":"10.1111\/bjh.18868"},{"key":"72904","doi-asserted-by":"crossref","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed\/ refractory mantle cell lymphoma. Blood. 2022; 139(5):666-677.","DOI":"10.1182\/blood.2021013326"},{"key":"72905","doi-asserted-by":"crossref","unstructured":"Ryan CE, Zon RL, Redd R. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023; 203(5):774-780.","DOI":"10.1111\/bjh.19037"},{"key":"72906","doi-asserted-by":"crossref","unstructured":"Lewis KL, Cheah CY. Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: progress, but not perfect. Br J Haematol. 2023; 203(5):701-703.","DOI":"10.1111\/bjh.19095"},{"key":"72907","doi-asserted-by":"crossref","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024; 403(10441):2293-2306.","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"72908","doi-asserted-by":"crossref","unstructured":"Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016; 27(5):778-787.","DOI":"10.1093\/annonc\/mdw029"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11822\/77753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11822\/78092","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11822\/77753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:36Z","timestamp":1794046056000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286205","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}